Each item is reproduced from the Explanation & Elaboration document published alongside the CINEX guideline: the reporting requirement itself, why it matters, the specific points a study should cover, and worked examples.

29 items

Information model 5 items

  • IM1

    Details of extracted information types

    Item 1

    Clearly list and define each type of clinical information the algorithm is designed to extract, such as entities (medications, diagnoses, procedures, or laboratory values), relations or document classes. Provide examples for each type, especially when extracting complex, multi-part types and/or concepts.

  • IM2

    Underlying clinical information model

    Item 2

    Describe the underlying clinical information model or clinical framework used to guide the structuring or interpretation of extracted data, if applicable. Furthermore, justify the choice of model and its context. Describe any adaptations or assumptions made and limitations of the information model.

  • IM3

    Data model

    Item 3

    Describe the underlying data model used to guide the structuring or interpretation of extracted data, if applicable.

  • IM4

    Semantic aspects of the extraction process

    Item 4

    Explain how extracted entities are organized by mapping to terminologies, ontologies, or thesauri.

  • IM5

    Complementing aspects of the extraction process

    Item 5

    If applicable, describe how uncertainty, negation, temporality, ambiguity, inconsistency and coreference resolution (e.g., patient vs. family member) is handled.

Architecture 5 items

  • A1

    Task

    Item 6

    Describe the primary information extraction task (s) as well as additional steps performed as part of the study, such as document classification, named entity recognition (NER), relation extraction, template filling, or summarization. For complex workflows (e.g., agentic behaviour, multi-step pipelines), describe each step in detail.

  • A2

    Implementation

    Item 7

    Detail the implementation strategy used to develop the algorithm, including any specific frameworks, pipelines, or approaches. When using existing software, include version specifiers and parameters. If applicable, depict the complete machine learning system architecture including its components. For LLMs, provide the model card.

  • A3

    Pre-processing

    Item 8

    Describe text normalization or cleaning steps performed prior to model input, including the rationale and details of the approach taken. When using existing software, include version specifiers and parameters.

  • A4

    Hyperparameters

    Item 9

    List all hyperparameters used during model training and provide their values and selection process (manual, grid search, etc.). For incontext learning, provide the exact prompts used and describe the prompt development process.

  • A5

    Hardware details

    Item 10

    Report hardware specifications (e.g., GPU device name, vRAM, cluster description, GPU hours) of training and inference environments and costs, if applicable and available.

Data 9 items

  • D1

    Data flow

    Item 11

    Provide a detailed description of the data processing workflow, to report on the processing of selecting, excluding, filtering and sampling data from the originally available pool of documents and on the number of resulting documents/sentences/words/tokens for each step. The provision of a visualization is complementary.

  • D2

    Splitting strategy

    Item 12

    Show and explicitly describe the applied data splitting strategy (train, test, evaluation and/or validation set) including amount of documents/sentences/words/tokens, splitting modality (timeline, groups, etc.), and method (random, stratified).

  • D3

    Origin

    Item 13

    Identify the department (s), institution (s) and country (ies) from which the clinical texts originated. If applicable, describe which (clinical) information system data was extracted from.

  • D4

    Type

    Item 14

    Describe the clinical text source (author type, stage in patient treatment where it is created (e.g., at discharge, during stay) and their purpose (e.g., progress monitoring) and content (e.g., daily insights from nurses).

  • D5

    Timeframe

    Item 15

    Describe the timeframe and (binned) time-related distribution of the dataset.

  • D6

    Representativeness and imbalance measures

    Item 16

    Describe the population the data used in the study might be representative for, including any limitations. If applicable, report the class distribution on all levels (source, sample, split) and any methods used to address class imbalance.

  • D7

    Examination and medical specialty

    Item 17

    If applicable, describe the examination and medical specialty the document corresponds to.

  • D8

    Language

    Item 18

    Specify the language (s) of the clinical texts used for algorithm development and evaluation. Describe any manipulation of the original data (e.g. translation).

  • D9

    Ethical Approval

    Item 19

    State whether the study received ethics committee approval and provide the approval reference number if applicable.

Annotation 5 items

  • AN1

    Annotation Approach

    Item 20

    Describe whether the textual annotation method is manual, rule-based, machine learning-based, or hybrid (i.e., if automated annotation was combined with manual annotation), including its sequence. Describe the applied tagging format, if applicable.

  • AN2

    Annotation Process

    Item 21

    Detail the annotation process, including annotator background, roles, training, as well as number of annotators and test rounds.

  • AN3

    Annotation Guidelines

    Item 22

    Describe the annotation guidelines used, including how they were developed, tested, and refined. Explicitly state whether the guidelines are publicly available.

  • AN4

    Annotation Tools

    Item 23

    Mention any software used to support the guideline development and annotation process.

  • AN5

    Inter-Annotator Agreement

    Item 24

    Describe how annotation consistency was measured and report the agreement metrics used, as well as how disagreements were handled.

Outcome 5 items

  • O1

    Performance

    Item 25

    Provide detailed performance metrics for each information type as well as aggregated over all types, such as precision, recall, and F1- score. Justify each metric used. Explicitly state the calculation formula for each metric. For continuous variables, show the risk for outliers (e.g., scatterplots). Describe the aggregation method used for calculating averaged performance measures. If available, compare with human-level and baseline performance. Describe (manual) error analysis results. For classification tasks, provide confusion matrices.

  • O2

    Statistical Validation

    Item 26

    Describe any statistical validation procedures applied.

  • O3

    External validation

    Item 27

    If applicable, report results of validating the information extraction algorithm on an independent dataset from another institution than the training / test data and detail the dataset’s characteristics. If external validation is not possible, it should be acknowledged as limitation.

  • O4

    Data availability

    Item 28

    Indicate whether and how the datasets used in the study are publicly available, accessible upon request, or not available (including a rationale).

  • O5

    Source Code Availability

    Item 29

    Explicitly state whether the source code is made available. If yes, provide it via open repositories (e.g., Zenodo). If applicable, provide links to trained models (either via upload to a platform or direct download).